A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with diabetes lower blood sugar.

Recruiting now. Registry record last updated February 27, 2026.

Who can join: Adults 18+, have diabetes, BMI 27+.
What you take: Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 3 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 1Sponsor M.D. Anderson Cancer CenterDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 30

What this study is for

Primary condition: Diabetes. Also studied in: Prostate Cancer.

Full scientific study title: Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study.

Who can join

Age18 and upSexMaleBMI27 or higher

Adults 18+, have diabetes, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Histologically confirmed adenocarcinoma of the prostate that is localized (no metastatic lesions or concerning lymph nodes 1 cm or greater) based on prostate MRI and meets NCCN intermediate risk criteria (as follows):
Clinical T2b-T2c or lower disease
Gleason Grade group 2 or 3 on biopsy
PSA ≤20 ng/mL
Desires radical prostatectomy (open or robotic) for prostate cancer management and is a surgical candidate as determined by the treating urologic oncologist

Key exclusion criteria

Prostate cancer that meets factors as part of NCCN high and very high-risk criteria (as follows):
pT3a or higher disease
Grade group 4 or 5 adenocarcinoma of prostate
Presence of metastatic disease on imaging
A history of intentional or unintentional weight loss of more than 5 kg within 90 days of screening

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Texas1 site

The University of Texas M. D. Anderson Cancer Center
Houston, Texas
Justin Gregg, MD713-792-3250jrgregg@mdanderson.org

Follow this trial

We email you if NCT06759701 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: July 2, 2025. Expected completion: December 31, 2028. Last updated on ClinicalTrials.gov: February 27, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.